Skip to main content
Triangle logo TriangleGet started

BAY2927088 (NCT06760819)

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2): a one-minute explainerNCT067608191 min

BAY2927088 trial for Advanced Solid Tumors (NCT06760819). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with unresectable or metastatic solid tumors carrying an activating HER2 mutation, after standard treatment or without satisfactory alternatives. Non-small cell lung cancer, prior HER2 kinase inhibitors and active brain metastases are excluded.

The idea: take sevabertinib tablets twice daily. This medicine targets abnormal HER2 signaling that drives cancer-cell growth. Everyone receives the study medicine; there is no comparison group. Researchers measure tumor responses and monitor safety through scans, heart checks and laboratory tests.

This phase 2 study plans 111 patients. Bayer sponsors six recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.